Arvat E, Giordano R, Ramunni J, Arnaldi G, Colao A, Deghenghi R, Lombardi G, Mantero F, Camanni F, Ghigo E
Division of Endocrinology, University of Turin, Ancona, Italy.
J Clin Endocrinol Metab. 1998 Dec;83(12):4207-11. doi: 10.1210/jcem.83.12.5355.
We previously reported that in Cushing's disease (CD) the ACTH- and cortisol (F)-releasing activity of Hexarelin (HEX), a GH secretagogue, is exaggerated with respect to that in normal subjects and is higher than that of human CRH (hCRH), but it is absent in Cushing's syndrome. Our aim was to extend the study about the effects of HEX (2.0 microg/kg, iv) on ACTH and F secretion in 21 patients with CD (3 men and 18 women, 16-68 yr old). Based on magnetic resonance imaging, 15 CD patients had pituitary microadenoma, and 6 had macroadenoma. The results in CD patients were compared with those in 27 normal age-matched controls (NS; 10 men and 17 women, 24-69 yr old). Basal ACTH and F levels in CD were similar in patients with microadenom (mean+/-SEM, 78.3+/-7.2 pg/mL and 237.1+/-23.6 microg/L, respectively) and macroadenoma (57.4+/-9.0 pg/mL and 196.9+/-20.1 microg/L, respectively) and were higher (P < 0.001) than those in NS (17.7+/-2.0 pg/mL and 115.3+/-6.7 microg/L, respectively). In microadenoma CD patients, HEX induced marked ACTH and F increases (delta peak, mean+/-SEM: 261.2+/-77.6 pg/mL and 226.1+/-87.2 microg/L, respectively), which were higher (P < 0.04) than those induced by hCRH (45.6+/-16.9 pg/mL and 84.6+/-25.7 microg/L, respectively). Moreover, in microadenoma CD patients, the ACTH and F responses to HEX were higher (P < 0.001) than those in NS (18.5+/-4.0 pg/mL and 36.1+/-6.8 microg/L, respectively). In macroadenoma CD patients, HEX induced a slight, but significant increase (P < 0.02) in ACTH and F levels (33.9+/-18.0 pg/mL and 89.6+/-34.3 microg/L, respectively), which was not significantly different from that elicited by hCRH (20.0+/-7.0 pg/mL and 54.8+/-21.3 microg/L, respectively). In macroadenoma CD patients, the ACTH and F responses to HEX and hCRH were, in turn, similar to those in NS. In conclusion, our findings demonstrate that the ACTH and F hyperresponsiveness to HEX is present in Cushing's disease with micro-, but not macro- ACTH-secreting pituitary adenoma. This finding agrees with other evidence pointing toward differences in the hormonal behavior between micro- and ACTH-secreting pituitary macroadenomas.
我们之前报道过,在库欣病(CD)中,生长激素促分泌素Hexarelin(HEX)的促肾上腺皮质激素(ACTH)和皮质醇(F)释放活性相对于正常受试者被夸大,且高于人促肾上腺皮质激素释放激素(hCRH),但在库欣综合征中不存在这种情况。我们的目的是扩展关于HEX(2.0微克/千克,静脉注射)对21例CD患者(3名男性和18名女性,年龄16 - 68岁)ACTH和F分泌影响的研究。基于磁共振成像,15例CD患者有垂体微腺瘤,6例有大腺瘤。将CD患者的结果与27名年龄匹配的正常对照者(NS;10名男性和17名女性,年龄24 - 69岁)的结果进行比较。CD患者中微腺瘤患者(平均±标准误,分别为78.3±7.2皮克/毫升和237.1±23.6微克/升)和大腺瘤患者(57.4±9.0皮克/毫升和196.9±20.1微克/升)的基础ACTH和F水平相似,且高于NS组(分别为17.7±2.0皮克/毫升和115.3±6.7微克/升,P < 0.001)。在微腺瘤CD患者中,HEX引起ACTH和F显著增加(峰值变化,平均±标准误:分别为261.2±77.6皮克/毫升和226.1±87.2微克/升),高于hCRH引起的增加(分别为45.6±16.9皮克/毫升和84.6±25.7微克/升,P < 0.04)。此外,在微腺瘤CD患者中,对HEX的ACTH和F反应高于NS组(分别为18.5±4.0皮克/毫升和36.1±6.8微克/升,P < 0.001)。在大腺瘤CD患者中,HEX引起ACTH和F水平轻微但显著增加(P < 0.02,分别为33.9±18.0皮克/毫升和89.6±34.3微克/升),与hCRH引起的增加(分别为20.0±7.0皮克/毫升和54.8±21.3微克/升)无显著差异。在大腺瘤CD患者中,对HEX和hCRH的ACTH和F反应依次与NS组相似。总之,我们的研究结果表明,在分泌ACTH的垂体微腺瘤而非大腺瘤导致的库欣病中存在对HEX的ACTH和F高反应性。这一发现与其他表明分泌ACTH的垂体微腺瘤和大腺瘤之间激素行为存在差异的证据一致。